Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Nov 1;134(18):1308-1310.
doi: 10.1161/CIRCULATIONAHA.116.023263. Epub 2016 Sep 12.

Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? A Protagonist View From the SPRINT Trial (Systolic Blood Pressure Intervention Trial)

Suzanne Oparil  1 , Cora E Lewis  2
Affiliations
Randomized Controlled Trial

Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? A Protagonist View From the SPRINT Trial (Systolic Blood Pressure Intervention Trial)

Suzanne Oparil et al. Circulation. .
No abstract available

Keywords: blood pressure; blood pressure measurement/monitoring; clinical trial; high blood pressure; hypertension.

PubMed Disclaimer

Conflict of interest statement

Suzanne Oparil reports grant/personal fees/non-financial support from NHLBI, Forest laboratories, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, GlaxoSmithKline, Merck and Co., Novartis, Arbor Pharmaceuticals LLC. She served as co-chair of the JNC 8 committee and participated in the previous JNC guidelines writing committees. She is a writing group member of the World Heart Federation (WHF), European Society of Hypertension (ESH), European Public Health Association (EPH) Global Working Group on Optimal Salt Consumption and Cardiovascular Health. Dr. Oparil serves as Director/PI of the UAB Clinical Center Network (CCN) for the NIH/NHLBI-funded Systolic Blood Pressure Intervention Trial (SPRINT), and as sub-investigator for a UAB CCN clinical site UAB Hypertension Clinic (Site PI: Calhoun, DA). Cora E Lewis reports grant funding from NIH and Novo Nordisk (unrelated to this topic). Dr. Lewis serves as Co-PI of the UAB Clinical Center Network (CCN) for the NIH/NHLBI-funded Systolic Blood Pressure Intervention Trial (SPRINT),

References

    1. Wright JT, Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116. doi: 10.1056/NEJMoa1511939. - DOI - PMC - PubMed
    1. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT, Jr, Pajewski NM SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: A randomized clinical trial. JAMA. 2016 May 19; doi: 10.1001/jama.2016.7050. - DOI - PMC - PubMed
    1. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of results from the Systolic Blood Pressure Intervention Trial (SPRINT) to the US adult population. J Am Coll Cardiol. 2016;67:463–472. doi: 10.1016/j.jacc.2015.10.037. - DOI - PMC - PubMed
    1. Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH, Jr, Lipkin EW, Narayan KM, Riddle MC, Jr, Sood A, Goff DC., Jr Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721–8. - PMC - PubMed
    1. Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Harris KC, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM CHEP Guidelines Task Force. Hypertension Canada’s 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol. 2016;32:569–588. doi: 10.1016/j.cjca.2016.02.066. - DOI - PubMed

Publication types